ES2106721T3 - Uso de amilina o cgrp para el tratamiento de la diabetes mellitus. - Google Patents

Uso de amilina o cgrp para el tratamiento de la diabetes mellitus.

Info

Publication number
ES2106721T3
ES2106721T3 ES88307927T ES88307927T ES2106721T3 ES 2106721 T3 ES2106721 T3 ES 2106721T3 ES 88307927 T ES88307927 T ES 88307927T ES 88307927 T ES88307927 T ES 88307927T ES 2106721 T3 ES2106721 T3 ES 2106721T3
Authority
ES
Spain
Prior art keywords
peptide
treatment
diabetes mellitus
high performance
liquid chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307927T
Other languages
English (en)
Inventor
Garth James Smith Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2106721T3 publication Critical patent/ES2106721T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

AMILINAS O NH2 - AMILINA O CGRP O UN PEPTIDO FUNCIONAL FRAGMENTO DE AMILINA O NH2 - AMILINA O CGRP O UNA VARIANTE CONSERVATIVA DE LA AMILINA O NH2 - AMILINA O CGRP O FRAGMENTOS, SE PREVEE TAMBIEN UNA AMILINA SOLUBLE O AMILINA - AMIDA O UN SUBFRAGMENTO DE ELLOS O UN PRODUCTO LIPOFILICO PARA USDO EN TRATAMIENTO DE DIABETES MELLITUS O HIPOGLICEMIA. SE PREVEEN METODOS PARA SU PREPARACION.
ES88307927T 1987-08-26 1988-08-26 Uso de amilina o cgrp para el tratamiento de la diabetes mellitus. Expired - Lifetime ES2106721T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878720115A GB8720115D0 (en) 1987-08-26 1987-08-26 Treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
ES2106721T3 true ES2106721T3 (es) 1997-11-16

Family

ID=10622830

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307927T Expired - Lifetime ES2106721T3 (es) 1987-08-26 1988-08-26 Uso de amilina o cgrp para el tratamiento de la diabetes mellitus.

Country Status (15)

Country Link
US (2) US5124314A (es)
EP (2) EP0787741A1 (es)
JP (1) JP2828250B2 (es)
AT (1) ATE155688T1 (es)
AU (1) AU634954B2 (es)
CA (1) CA1341060C (es)
DE (1) DE3855970T2 (es)
DK (1) DK473888A (es)
ES (1) ES2106721T3 (es)
FI (1) FI883936A (es)
GB (1) GB8720115D0 (es)
GR (1) GR3024705T3 (es)
HK (1) HK1000934A1 (es)
NO (1) NO883828L (es)
SG (1) SG93776A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
JP2533726Y2 (ja) * 1990-07-23 1997-04-23 船井電機株式会社 記録再生機器
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (en) * 1991-03-15 1992-09-16 Pfizer Inc. Amylin and calcitonin gene-related peptide use and antagonists thereof
ATE197764T1 (de) * 1991-05-24 2000-12-15 Amylin Pharmaceuticals Inc Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
ATE157010T1 (de) * 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
DE69232064T2 (de) * 1991-11-19 2002-03-28 Amylin Pharmaceuticals Inc Peptide als Amylin-Agonisten und ihre Verwendung
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
ES2122010T3 (es) * 1992-08-06 1998-12-16 Pfizer Muteinas de amilina.
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5545672A (en) * 1993-02-11 1996-08-13 The University Of Texas System Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
ZA946881B (en) * 1993-09-07 1995-10-30 Amylin Pharmaceuticals Inc Methods for treating gastrointestinal motility
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5922677A (en) * 1994-07-13 1999-07-13 Auckland Uniservices Limited Therapeutic method and compounds of use therein
DE122005000033I2 (de) 1994-10-21 2006-11-23 Nps Pharma Inc Kalzium-Receptor aktive Verbindungen
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
EP0910578A2 (en) * 1996-01-19 1999-04-28 The Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
PT907631E (pt) 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
AU5916298A (en) * 1998-01-09 1999-07-26 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CN1296384C (zh) * 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 具有preptin功能的肽
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
EP1196189A2 (en) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP2004517050A (ja) * 2000-09-19 2004-06-10 ユニバーシティ オブ トロント Ｉａｐｐ原線維形成の抑制剤およびそれらの使用
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CN1617737A (zh) * 2001-11-26 2005-05-18 普罗特米克斯公司 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
ES2316757T3 (es) * 2002-01-08 2009-04-16 Amylin Pharmaceuticals, Inc. Uso de agonistas de amilina para modular trigliceridos.
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP1638546A1 (en) * 2003-07-01 2006-03-29 Essentys AB Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
RU2385878C2 (ru) * 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
US20080032915A1 (en) * 2004-02-12 2008-02-07 Campina Nederland Holding B.V. Cysteine Rich Peptides for Improving Thiol Homeostasis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CA2699035A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
KR20100061486A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
EP2762150A1 (en) 2009-03-12 2014-08-06 Nordic Bioscience A/S Treatment of Diabetes and Metabolic Syndrome
WO2011067283A1 (en) 2009-12-01 2011-06-09 Novo Nordisk A/S Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
CA2916980C (en) 2013-07-03 2023-02-21 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
US10772556B2 (en) 2014-11-05 2020-09-15 Cláudio Afonso Ambrósio Method and system for monitoring and treating hypoglycemia
EP3562500B1 (fr) 2016-12-27 2023-07-19 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
IL272141B1 (en) 2017-07-27 2024-03-01 Adocia Preparations in the form of an aqueous solution for injection containing at least human insulin A21G and suppressing glucagon activity with a meal
FR3082426A1 (fr) 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019115411A1 (fr) 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CA3084688A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
SG11202005319PA (en) 2017-12-07 2020-07-29 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
EP3740195A1 (fr) 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CA3084689A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2141430B (en) * 1983-06-15 1987-01-21 Kingdon Craig R Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
US4736023A (en) * 1983-12-23 1988-04-05 The Salk Institute For Biological Studies DNA encoding human CGRP
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
EP0188400B1 (de) * 1985-01-16 1992-07-08 Ciba-Geigy Ag Oligopeptide sowie Zwischenprodukte und Verfahren zu ihrer Herstellung
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
US4697002A (en) * 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
ES2052583T3 (es) * 1986-12-04 1994-07-16 Asahi Chemical Ind Derivados de peptidos relacionados con el gel calcitonina.
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides

Also Published As

Publication number Publication date
EP0309100A2 (en) 1989-03-29
SG93776A1 (en) 2003-01-21
JP2828250B2 (ja) 1998-11-25
GR3024705T3 (en) 1997-12-31
NO883828L (no) 1989-02-27
AU634954B2 (en) 1993-03-11
DE3855970D1 (de) 1997-09-04
EP0309100A3 (en) 1991-04-03
DK473888D0 (da) 1988-08-25
ATE155688T1 (de) 1997-08-15
NO883828D0 (no) 1988-08-26
CA1341060C (en) 2000-07-25
HK1000934A1 (en) 1998-05-08
JPH0196137A (ja) 1989-04-14
EP0787741A1 (en) 1997-08-06
DK473888A (da) 1989-04-05
DE3855970T2 (de) 1998-01-29
FI883936A (fi) 1989-02-27
FI883936A0 (fi) 1988-08-25
AU2157588A (en) 1989-07-20
GB8720115D0 (en) 1987-09-30
EP0309100B1 (en) 1997-07-23
US5124314A (en) 1992-06-23
US5641744A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ES2106721T3 (es) Uso de amilina o cgrp para el tratamiento de la diabetes mellitus.
Lafeber et al. Identification of hypocalcin (teleocalcin) isolated from trout Stannius corpuscles
Lee Elapid neurotoxins and their mode of action
LU91014I2 (fr) Kogentate (Octocog alfa) dans toutes ses formes couvertes par le brevet de base
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
DE3877753T2 (de) Transformierender wachstumsfaktor-beta.
FI904951A0 (fi) Vaevnadsplasminogenaktivatorderivat.
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
ATE145241T1 (de) Polypeptid, das zur interaktion mit thrombin fähig ist
ES2138973T3 (es) Muteinas de il-6 exentas de cisteina.
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
DE2540544C2 (de) (1-47)-Urogastron und das entsprechende durch Reduktion der Disulfidbindungen erhältliche Polypeptid, Verfahren zu deren Herstellung und diese Polypeptide enthaltende pharmazeutische Zusammensetzungen
Kobayashi et al. Amino acid sequence of porcine cardiac muscle troponin C
Lopez-Trascasa et al. Isolation and characterization of a biologically active C2 derived oligopeptide
Lafeber Comparison of PTH and hypocalcin in mammalian and teleost bioassays
Monahan et al. Studies of the interaction of C8 and C9 within the membrane-bound cytolytic complex of complement
Sanger Les Prix Nobel en
JPS5750948A (en) Insulin analog and preparation
TH13771EX (th) ชุดวินิจฉัยและวัคซีนของโรคตับอักเสบซี
DK411686A (da) Peptider

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 309100

Country of ref document: ES